"Treat first, ask questions later" is typically the procedure for treating bacterial infections because the answers to those questions take a couple of days to elucidate while the lab cultures the bacteria to determine the strain. Read More
Last year's approvals of hemophilia A therapies Nuwiq (simoctocog alfa) from Octapharma AG, of Lachen, Switzerland, and long-acting Adynovate (antihemophilic factor [recombinant], pegylated) from Baxalta Inc. (now part of Shire plc) capped a two-year rush of products to treat bleeding disorders following a long dry spell in the space. As the American Society of Hematology (ASH) annual meeting prepares to kick off this week in San Diego, analysts are handicapping the next generation of treatments, designed to extend therapeutic benefits from days to weeks, and watching for clues on the trajectory of potentially curative gene therapies. Read More
